Patents by Inventor James Miller Suttie

James Miller Suttie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating Urothelial Carcinoma Using Genotypic and Phenotypic Biomarkers
    Publication number: 20190203300
    Abstract: New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 4, 2019
    Applicant: Pacific Edge Limited
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof
    Patent number: 10131955
    Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 20, 2018
    Assignee: PACIFIC EDGE LIMITED
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Triaging of Patients Having Asymptomatic Hematuria Using Genotypic and Phenotypic Biomarkers
    Publication number: 20170275697
    Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 28, 2017
    Applicant: Pacific Edge Limited
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Deer antler extract for promoting angiogenesis
    Patent number: 8067364
    Abstract: An isolated extract of deer velvet which contains components which have molecular weights that are substantially are less than or equal to 10 kDa and which have a proliferative effect on endothelial cells and/or promote angiogenesis.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: November 29, 2011
    Assignee: Velvet Antler Research New Zealand Limited (VARNZ)
    Inventors: Dawn Elizabeth Coates, Stephen Roy Haines, James Miller Suttie
  • DEER ANTLER EXTRACT FOR PROMOTING ANGIOGENESIS
    Publication number: 20090238892
    Abstract: An isolated extract of deer velvet which contains components which have molecular weights that are substantially are less than or equal to 10 kDa and which have a proliferative effect on endothelial cells and/or promote angiogenesis.
    Type: Application
    Filed: May 21, 2009
    Publication date: September 24, 2009
    Applicant: VELVET ANTLER RESEARCH NEW ZEALAND LIMITED (VARNZ)
    Inventors: DAWN ELIZABETH COATES, STEPHEN ROY HAINES, JAMES MILLER SUTTIE